Lipid nanoparticle encapsulated RNA (RNA-LNP) vaccines have played a pivotal role in the global response to the COVID-19 pandemic and are now at various stages of development against a wide-range of other infectious diseases.
Limited access to potent ionizable lipids, a key component in LNPs, and expertise for formulation and scale-up, present real barriers to entry in this field.
To overcome these challenges, we developed and optimized a novel ionizable lipid and a corresponding LNP composition for the delivery of RNA in vaccine applications.
Learn more at www.cytiva.com
6 май 2024
